BioCentury
ARTICLE | Company News

Emisphere drug delivery news

September 24, 2012 7:00 AM UTC

Following last year's discontinuation of musculoskeletal compound SMC021, Emisphere said it will focus on launching its Eligen Oral B12 product. Emisphere hired Alan Rubino as president, CEO and a director. Rubino is formerly CEO and president of New American Therapies Inc. (New York, N.Y.). Additionally, the company appointed Timothy Rothwell, a director, as chairman. Rothwell is formerly chairman of the Sanofi-Aventis U.S. unit of Sanofi (Euronext:SAN; NYSE:SNY, Paris France). The Eligen Oral B12 product is 1,000 µg vitamin B12 for use by B12-deficient subjects. The product is based on the company's Eligen oral drug delivery technology, which facilitates the absorption of small and large molecules without altering their chemical form, biological integrity or pharmacological properties. At June 30, Emisphere had $1.4 million in cash and a six-month operating loss of $3.2 million. ...